

ASX Announcement

7 August 2023

Commencement of Chief Executive Officer

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY], a biotechnology company focused on the development of novel therapies for rare diseases, is pleased to announce the commencement of Dr James Garner as Chief Executive Officer and Managing Director, effective 7 August 2023.

Dr Garner's appointment was previously announced to ASX on 8 May 2023, and he has served as a non-executive Director of the company since that date. Dr Garner is a physician and MBA graduate, and brings to Antisense more than twenty years of international experience in drug development, gleaned in companies such as Biogen (NASDAQ: BIIB), Sanofi (NASDAQ: SNY), Takeda (TSE: 4502.T), and, most recently, as Chief Executive Officer and Managing Director of Kazia Therapeutics Limited (NASDAQ: KZIA). Prior to joining the pharmaceutical industry, Dr Garner worked as a management consultant with Bain & Company.

As part of the leadership transition, Dr Charmaine Gittleson will step back from executive responsibilities and will resume her role as Non-Executive Chair of the company.

"This is an exciting time for Antisense, and I am very much looking forward to joining the team," commented Dr Garner. "Recruitment to our international phase IIb study of ATL1102 in Duchenne muscular dystrophy is well underway, and our recent successful financing round demonstrates that the company enjoys strong interest from investors. My first priorities as CEO will be to ensure the continued momentum of the ATL1102 study, to build on our partnering outreach, and to begin the process of preparing ATL1102 for potential commercialisation."

~ ENDS ~

This announcement has been authorised for release by the Board.

About Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company developing and commercializing antisense pharmaceuticals for rare diseases with significant unmet medical need. The company's lead program is ATL1102, an antisense inhibitor of the CD49d receptor, which is currently the subject of an ongoing international Phase IIb trial for non-ambulant subjects with Duchenne Muscular Dystrophy. The drug previously reported highly promising results from an exploratory Phase II trial in non-ambulant subjects with DMD.

For more information, please contact info@antisense.com.au